


AUG 21 2000


FORM PTO-1449 (Modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use Several Sheets If Necessary)  (37 CFR § 1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: UM-03662	Serial No.: 09/291,656
	Applicant: Marc Peters-Golden <i>et al.</i>		
	Filing Date: 3/3/99	Group Art Unit: 1651	

**U.S. PATENT DOCUMENTS**

Examiner Initials	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
----------------------	---------------------------	------------	----------------------	-------	----------	-------------

**OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)**

	1	M. Lohmann-Matthes <i>et al.</i> , "Pulmonary Macrophages," <i>Eur. Respir. J.</i> 7:1678-1689 (1994);
	2	J. Langermans <i>et al.</i> , "Antimicrobial Functions of Mononuclear Phagocytes," <i>J. Immunol. Methods</i> 174:185-194 (1994);
	3	S. Nelson <i>et al.</i> , "Pathology of Pneumonia," <i>Clin. Chest Med.</i> 16(1):1-12 (1995)
	4	E. Goetzl <i>et al.</i> , "Specificity of Expression and Effects of Eicosanoid Mediators in Normal Physiology and Human Diseases," <i>FASEB J</i> 9:1051-1058 (1995);
	5	J. Woods <i>et al.</i> , "5-Lipoxygenase Is Located In the Euchromatin of the Nucleus in Resting Human Alveolar Macrophages and Translocates to the Nuclear Envelope Upon Cell Activation," <i>J. Clin. Invest.</i> 95:2035-2040 (1995);
	6	M. Peters-Golden <i>et al.</i> , "Alterations In the Pattern of Arachidonate Metabolism Accompany Rat Macrophage Differentiation In the Lung," <i>J. Immunol.</i> 144(1):263-270 (1990);
	7	T. Martin <i>et al.</i> , Relative Contribution of Leukotriene B <sub>4</sub> to the Neutrophil Chemotactic Activity Produced by the Resident Human Alveolar Macrophage," <i>J. Clin. Invest.</i> 80:1114-1124 (1989);
	8	T. Martin <i>et al.</i> , Effects of leukotriene B <sub>4</sub> in the Human Lung. Recruitment of Neutrophils Into the Alveolar Spaces Without a Change in Protein Permeability, <i>J. Clin. Invest.</i> 84(5):1609-1619
	9	T. Demitsu <i>et al.</i> , "Phagocytosis and Bactericidal Action of Mouse Peritoneal Macrophages Treated With Leukotriene B <sub>4</sub> ," <i>Int. J. Immunopharmac.</i> 11(7):801-808 (1989);
	10	P. Marder <i>et al.</i> , "Blockade of Human Neutrophil Activation by 2-[2-Propyl-3-[2-[Ethyl-4-(4-Fluorophenyl)-5-Hydroxyphenoxy]Propoxy]Phenoxy]Benzoic Acid (LY293111), A Novel Leukotriene B <sub>4</sub> Receptor Antagonist," <i>Biochem. Pharmacol.</i> 49(11):1683-1690 (1995);
	11	C. Serhan <i>et al.</i> , "Leukotriene B <sub>4</sub> Is A Complete Secretagogue In Human Neutrophils: A Kinetic Analysis," <i>Biochem. Biophys. Res. Commun.</i> 107(3):1006-1012 (1982);
	12	J. Wijkander <i>et al.</i> , "5-Lipoxygenase Products Modulate the Activity of the 85-kDa Phospholipase A <sub>2</sub> in Human Neutrophils," <i>J. Biol. Chem.</i> 270(44):26543-26549 (1995);
	13	J. O'Flaherty <i>et al.</i> , "Mechanisms Involved In the Bidirectional Effects of Protein Kinase C Activators on Neutrophil Responses to Leukotriene B <sub>4</sub> ," <i>J. Immunol.</i> 144(5):1909-1913 (1990);
	14	R. Strieter <i>et al.</i> , "Cytokine-induced Neutrophil-derived Interleukin-8," <i>Am. J. Pathol.</i> 141(2):397-407 (1992)
	15	R. Bray and Z. Brahmi, "Role of Lipoxygenation in Human Natural Killer Cell Activation," <i>J. Immunol.</i> 136(5):1783-1790 (1986)
	16	J. Rhodes <i>et al.</i> , "Macrophage Fcγ <sub>2b</sub> Receptor Expression and Receptor-Mediated Phospholipase Activity: Regulation By Endogenous Eicosanoids," <i>Eur. J. Immunol.</i> 15:222-227 (1985);
	17	M. Peppelenbosch <i>et al.</i> , "Epidermal Growth Factor-Induced Actin Remodeling Is Regulated by 5-Lipoxygenase and Cyclooxygenase Products," <i>Cell</i> 74:565-575 (1993);
	18	A. Buret <i>et al.</i> , Effector Mechanisms of Intestinally Induced Immunity To <i>Pseudomonas Aeruginosa</i> in the Rat Lung: Role of Neutrophils and Leukotriene B <sub>4</sub> , <i>Infect. Immun.</i> 61(2):671-679 (1993);
	19	H. Hopkins <i>et al.</i> , "Neutrophil Chemotactic Factors in Bacterial Pneumonia," <i>Chest</i> 95(5):1021-1027 (1989);
	20	R. Moqbel <i>et al.</i> , "Enhancement of Neutrophil- and Eosinophil-mediated Complement-dependent Killing of Schistosomula of <i>Schistosoma Mansoni</i> In Vitro By Leukotriene B <sub>4</sub> ," <i>Clin. Exp. Immunol.</i> 52:519-527 (1983);
	21	M. Balter <i>et al.</i> , "Different Patterns of Arachidonate Metabolism In Autologous Human Blood Monocytes and Alveolar Macrophages," <i>J. Immunol.</i> 142(2):602-608 (1989);
	22	T.G. Brock <i>et al.</i> , "Localization of 5-Lipoxygenase to the Nucleus of Unstimulated Rat Basophilic Leukemia Cells," <i>J. Biol. Chem.</i> 269(45):22059-22066 (1994);

Examiner: 	Date Considered: 3/15/01
<b>EXAMINER:</b> Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**BEST AVAILABLE COPY**

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UM-03662	Serial No.: 09/291,656
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use Separate Sheets If Necessary)				Applicant: Marc Peters-Golden <i>et al.</i>	
				Filing Date: 3/3/99	Group Art Unit: 1651
(37 CFR § 1.98(b))					
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
23	M. Balter <i>et al.</i> , "Multiple defects In Arachidonate Metabolism In Alveolar Macrophages From Young Asymptomatic Smokers," <i>J. Lab. Clin. Med.</i> 114:662-673 (1989);				
24	M. Coffey <i>et al.</i> , "5-Lipoxygenase Metabolism In Alveolar From Subjects Infected With the Human Immunodeficiency Virus," <i>J. Immunol.</i> 157:393-399 (1996);				
25	M.J. Coffey <i>et al.</i> , "Reduced 5-Lipoxygenase Metabolism of Arachidonic Acid in Macrophages From 1, 25-Dihydroxyvitamin D <sub>3</sub> -Deficient Rats," <i>Prostaglandins</i> . 48:313-329 (1994);				
26	J. Goulet <i>et al.</i> , "Altered Inflammatory Responses In Leukotriene-Deficient Mice," <i>Proc. Natl. Acad. Sci. USA</i> 91:12852-12856 (1994);				
27	X. Chen <i>et al.</i> , "Role of Leukotrienes Revealed By Targeted Disruption of the 5-Lipoxygenase Gene," <i>Nature</i> 372:179-182 (1994);				
28	McColm <i>et al.</i> , "Evaluation of Cefotaxime In Experimental <i>Klebsiella Pneumoniae</i> Pneumonia: Comparison With Other Antibiotics and Measurement of Its Penetration Into Respiratory Tissues and Secretions," <i>J. Antimicrob. Chemother.</i> 18:599-608 (1986);				
29	M. Greenberger <i>et al.</i> , "Neutralization of IL-10 Increases Survival In a Murine Model of <i>Klebsiella</i> Pneumonia," <i>J. Immunol.</i> 155:722-729 (1995);				
30	M. Schneemann <i>et al.</i> , "Nitric Oxide Synthase Is Not a Constituent of the Antimicrobial Armature of Human Mononuclear Phagocytes," <i>J. Infect. Dis.</i> 167:1358-1363 (1993);				
31	J. Wilborn <i>et al.</i> , "Constitutive Activation of 5-Lipoxygenase in the Lungs of Patients with Idiopathic Pulmonary Fibrosis," <i>J. Clin. Invest.</i> 97(8):1827-1836 (1996);				
32	L. Laichalk <i>et al.</i> , "Interleukin-10 Inhibits Neutrophil Phagocytic and Bactericidal Activity," <i>FEMS Immunol. Med. Microbiol.</i> 658:1-7 (1996);				
33	R. Crowell <i>et al.</i> , "Hyperoxic Suppression of Fc-γ Receptor-mediated Phagocytosis By Isolated Murine Pulmonary Macrophages," <i>Am. J. Respir. Cell Mol. Biol.</i> 12:190-195 (1995);				
34	W. Hsueh <i>et al.</i> , "LTB <sub>4</sub> Production and Lysosomal Enzyme Release by Rat Alveolar Macrophages: Effects of Phagocytosis, Receptor Binding, and Ionophore Stimulation," <i>Exp. Lung Res.</i> 13:385-399 (1987);				
35	G. Rosen <i>et al.</i> , "Free Radicals and Phagocytic Cells," <i>FASEB J.</i> 9:200-209 (1995);				
36	N. Hubbard and K. Erickson, Role of 5'-Lipoxygenase Metabolites in the Activation of Peritoneal Macrophages for Tumoricidal Function," <i>Mol. Immunol.</i> 160:115-122 (1995);				
37	N. Ahmed <i>et al.</i> , "Transgenic Mice Expressing Rabbit C-Reactive Protein Exhibit Diminished Chemotactic Factor-Induced Alveolitis," <i>Am. J. Respir. Crit. Care Med.</i> 153:1141-1147 (1996);				
38	W. Smith <i>et al.</i> , "Characterization of 5-Lipoxygenase Inhibitors In Biochemical and Functional <i>In Vivo</i> Assays," <i>J. Pharmacol. Exp. Ther.</i> 275:1332-1338 (1995);				
39	J. Drazen <i>et al.</i> , "Comparative Airway and Vascular Activities of Leukotrienes C-1 and <i>In Vivo</i> and <i>In Vitro</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 77:4354-4358 (1980);				
40	R. Harris <i>et al.</i> , "Clinical Activity of Leukotriene Inhibitors," <i>Int. J. Immunopharmac.</i> 17(2):147-156 (1995)				
41	R. Malaviya <i>et al.</i> , "Reversible Translocation of 5-Lipoxygenase in Mast Cells Upon IgE," <i>JBC</i> 268(7):4939-4944 (1993)				
42	I. Pavord <i>et al.</i> , "Effect of Inhaled Prostaglandin E <sub>2</sub> on Allergen-Induced Asthma," <i>Am Rev Respir. Dis</i> 148:87-90 (1993)				
43	M. Baile <i>et al.</i> , "Leukotriene-Deficient Mice Manifest Enhanced Lethality from <i>Klebsiella</i> Pneumonia in Association with Decreased Alveolar Macrophage Phagocytic and Bactericidal Activities," <i>The Journal of Immunology</i> 157:5221-5224 (1996)				
Examiner:	Date Considered: 3/15/01				
<b>EXAMINER:</b> Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

BEST AVAILABLE COPY